期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/ijms22168555
关键词
PPAR beta/delta; AMPK; GDF15; insulin resistance; type 2 diabetes mellitus
资金
- Ministerio de Economia y Competitividad of the Spanish Government [RTI2018-093999-B-100]
- CIBER de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM)
Activators of PPAR beta/delta show promise in preventing and treating type 2 diabetes mellitus, mainly through AMPK activation. Further understanding of the mechanisms underlying the effects of the PPAR beta/delta-AMPK pathway may provide a basis for the development of new therapies.
The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR)beta/delta show promise. Remarkably, most of the antidiabetic effects of PPAR beta/delta agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPAR beta/delta-AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPAR beta/delta-AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据